OSENI 12.5/45 12.5 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

oseni 12.5/45 12.5 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet blister pack

takeda pharmaceuticals australia pty ltd - alogliptin benzoate,pioglitazone hydrochloride -

OSENI 12.5/45 12.5 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

oseni 12.5/45 12.5 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet bottle

takeda pharmaceuticals australia pty ltd - alogliptin benzoate,pioglitazone hydrochloride -

OSENI 12.5/15 12.5 mg alogliptin (as benzoate) / 15 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

oseni 12.5/15 12.5 mg alogliptin (as benzoate) / 15 mg pioglitazone (as hydrochloride) film-coated tablet blister pack

takeda pharmaceuticals australia pty ltd - alogliptin benzoate,pioglitazone hydrochloride -

Olga Met 1000mg/12.5mg 1000 MG/1 TAB , (Benzoate) 12.5 MG/1 TAB Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

olga met 1000mg/12.5mg 1000 mg/1 tab , (benzoate) 12.5 mg/1 tab

الشركة الأردنية السويدية - jordan sweden medical & sterilization co. - metformin hcl 1000 mg/1 tab , alogliptin (benzoate) 12.5 mg/1 tab - 1000 mg/1 tab , (benzoate) 12.5 mg/1 tab

Nesina Met 12.5mg/1000mg Film-Coated Tablet Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

nesina met 12.5mg/1000mg film-coated tablet

takeda malaysia sdn bhd - metformin hydrochloride; alogliptin -

NESINA PIO 12.5/15 12.5 mg alogliptin (as benzoate) / 15 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

nesina pio 12.5/15 12.5 mg alogliptin (as benzoate) / 15 mg pioglitazone (as hydrochloride) film-coated tablet blister pack

takeda pharmaceuticals australia pty ltd - alogliptin benzoate,pioglitazone hydrochloride -

NESINA PIO 12.5/45 12.5 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

nesina pio 12.5/45 12.5 mg alogliptin (as benzoate) / 45 mg pioglitazone (as hydrochloride) film-coated tablet bottle

takeda pharmaceuticals australia pty ltd - alogliptin benzoate,pioglitazone hydrochloride -

OSENI 12.5/30 12.5 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

oseni 12.5/30 12.5 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet bottle

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg); pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, film coated - excipient ingredients: hypromellose; croscarmellose sodium; titanium dioxide; macrogol 8000; hyprolose; purified talc; iron oxide yellow; lactose monohydrate; magnesium stearate; microcrystalline cellulose; mannitol; iron oxide red; butan-1-ol; shellac; carnauba wax; ethanol absolute; glyceryl monooleate - oseni is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,oseni can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.

OSENI 12.5/30 12.5 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

oseni 12.5/30 12.5 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet blister pack

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg); pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; microcrystalline cellulose; mannitol; magnesium stearate; iron oxide red; lactose monohydrate; titanium dioxide; iron oxide yellow; macrogol 8000; hyprolose; purified talc; butan-1-ol; shellac; carnauba wax; ethanol absolute; glyceryl monooleate - oseni is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,oseni can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.

OSENI 25/30 25 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

oseni 25/30 25 mg alogliptin (as benzoate) / 30 mg pioglitazone (as hydrochloride) film-coated tablet blister pack

takeda pharmaceuticals australia pty ltd - alogliptin benzoate, quantity: 34 mg (equivalent: alogliptin, qty 25 mg); pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, film coated - excipient ingredients: titanium dioxide; mannitol; hypromellose; lactose monohydrate; hyprolose; macrogol 8000; croscarmellose sodium; magnesium stearate; iron oxide yellow; purified talc; microcrystalline cellulose; iron oxide red; shellac; ethanol absolute; iron oxide black; 1-butanol - oseni is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and pioglitazone is appropriate,- when treatment with metformin or pioglitazone alone does not provide adequate control; or,- in combination with metformin when dual therapy does not provide adequate control.,oseni can also be used to replace separate tablets of alogliptin and pioglitazone in patients already being treated with this combination.